+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Medicare's New Market-Based Reimbursement System for Clinical Laboratory Testing: Tipping Point Ahead for U.S. Labs in 2018 - Webinar

  • ID: 4548760
  • Webinar
  • June 2018
  • Region: Global
  • 90 Minutes
  • Compliance Online
Why Should You Attend:

This webinar will discuss how the lab payment cuts imposed by PAMA is shifting the competitive landscape for the U.S. laboratory industry. Specifically, the program will cover how the fallout from PAMA is altering the competitive dynamics between national and hospital outreach labs as well as providing a financial advantage to certain specialty labs offering proprietary tests and other labs performing advanced diagnostic laboratory tests (ADLTs).

Meantime, the very survival of small community labs along with some regional labs that serve niche markets, such as nursing homes, skilled nursing facilities and home bound patients is at stake. That’s because its these labs that are being hit the hardest by PAMA since they mostly perform a limited number of high-volume tests which are suffering the biggest cuts under the new Medicare market-based payment system. Finally, the webinar will discuss how the competitive reset will impact the trend toward industry consolidation.

Areas Covered in the Webinar:

Find out how the Medicare’s market-based payment methodology and resulting payment reductions is fundamentally shifting the laboratory industry’s competitive dynamics
Learn what legal and legislative initiatives are pending to modify the impact of future PAMA payment cuts under Medicare
Assess how competition between independent & hospital outreach labs is being reset by Medicare payment policies
Explain why lab outreach programs must be more transparent in their pricing and competitive in their pricing
Discover why lower Medicare pricing will affect lab rates for commercial payers
Understand why labs offering proprietary testing have a competitive advantage in today’s market
Determine why community and regional labs face the most danger from reduced Medicare rates and what steps they should consider in order to remain in business
Reveal how outreach lab programs can retain more advantageous reimbursement from commercial payers
Explore why labs should renegotiate future contracts with all outside suppliers including reagent and equipment vendors
Identify specific business strategies labs should consider to remain competitive in the volatile lab space
Discuss why Medicare payment policies are creating access problems for lab services in rural and inner city areas
Learn how the fallout from Medicare rate cuts will affect the future consolidation of the lab industry
Note: Product cover images may vary from those shown
Dennis Weissman, A nationally recognized, independent analyst and thought leader in the diagnostic field for over three decades, Dennis is President of Dennis Weissman & Associates, LLC, Falls Church, VA, a consultancy which provides market intelligence, M&A advisory services, business leadership and public policy advice to diagnostic and life science companies and organizations. He has expertise in Medicare and health care reform policies and trends; clinical lab and pathology payment & compliance policies as well as business trends affecting the diagnostic sector. Dennis founded and served as publisher of Washington G-2 Reports (now G2 Intelligence) through 1999, an information company that reports on and analyzes the U.S. clinical laboratory industry via newsletters, research reports and conferences. Prior to G2, he served as the Director of the Washington Office of the American Society for Medical Technology (now ASCLS) and before that, Special Assistant to the Deputy Assistant Secretary for Health, Department of Health, Education & Welfare (now HHS).
Note: Product cover images may vary from those shown